Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Apache Indian who wrote (423)	1/12/1999 1:08:00 PM
From: BRAVEHEART	Read Replies (1) \| Respond to of 1494

Hi Apache Indian, The goals for fiscal 1999 ( started Sept 1998 )are/were as follows. They are spelled out in the annual report. Product Development: 1. Initiate PIIB clinical trial for Diabetic Nuropathy. They accomplished this on Nov 2nd 1998. ntii.com The results are not due till the end of 1999. 2. Complete Phase IIB clinical trial for aids related dementia. This is projected to be completed in the spring. A more definitive time line. ntii.com 3. Complete PII clinical trial of XERECEPT for peritumoral brain edema. In a recent conversation with a company rep the enrollment for said trial has picked up pace over the last two months. This is a more difficult time line to nail down until full enrollment is achieved. 4. Grants Mgmt & Business Development: 1. Secure added financing. 2. Negotiate a collaboration with big pharma between NTI & MERZ. 3. Obtain Relisting. The above three will work in concert once they play out. Simply put the company needs added financing to compleat clinical trials. The company needs about $5 to $7 million to regain listing status. I expect the company to do some sort of inhouse financing or private placement initially. Then I would expect a deal with a major Pharma ( which will include sig cash upfront along with milestone payments ). At which point the company should have a cash position in excess of 7 to 11 million. At which time the shareprice should easily be above a buck. I'll argue that it will be in a range between 1.75 & 2.25. Ultimately this will allow the company to apply for relisting with NASDAQ. That will bring added liquidity to the issue. BEST WISHES LONE WOLF